Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report

BACKGROUND: Anaplastic thyroid cancer (ATC) is a rare but aggressive type of thyroid carcinoma. BRAF V600E-mutation, which is found in 10%-50% of ATCs, is associated with poor prognosis. A recent clinical trial reported a substantial clinical benefit of concomitant treatment of dabrafenib (BRAF inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Jae, Song, Si-Youn, Kim, Min Kyoung, Na, Hyung Gyun, Bae, Chang Hoon, Kim, Yong-Dae, Choi, Yoon Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601011/
https://www.ncbi.nlm.nih.gov/pubmed/37900238
http://dx.doi.org/10.12998/wjcc.v11.i27.6664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601011/
https://www.ncbi.nlm.nih.gov/pubmed/37900238
http://dx.doi.org/10.12998/wjcc.v11.i27.6664

Ejemplares similares